LONDON--(BUSINESS WIRE)--The global intrauterine contraceptive devices (IUD) market is expected to grow by USD 597.40 million as per Technavio. This marks a significant market slow down compared to ...

Please provide your email address to receive an email when new articles are posted on . Treatment success for the JADA system was high for both vaginal and cesarean births. Overall, 2.8% of women in ...

Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...

Under an agreement announced Monday, Feb. 23, Organon will pay $27.5 million upfront for the right to market Sebela’s Miudella, billed as the first FDA-approved device of its kind in 40 years.

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to ...

Hormonal intrauterine devices (IUDs), unlike oral contraceptives, were not linked with an increased risk for melasma in women with menorrhagia, this study found. Researchers analyzed data from the ...

Intrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during ...

Intrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during ...

According to a recent study, intrauterine devices (IUDs) used by women for contraception might lower the risk of getting cervix cancer compared to women who do not use this form of contraception. The ...